Hughes Violetta
Known title: CHIEF ACCOUNTING OFFICERCIK: 0001991429
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
AZTA Featured in Volatile Stock List. Azenta Inc. was included in a recent article discussing volatile stocks with promising prospects. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $37.00. This mention highlights the company's status as a high-beta asset in the current market environment.
Transaction History
| RGEN | ▼ Sell | Tax Withholding | 277 | $47K | 9/1/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 2,466 | $0 | 3/5/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 4,142 | $0 | 9/2/2025 | View on chart |
| AZTA | ▼ Sell | Open Market | 317 | $17K | 2/3/2025 | View on chart |
| AZTA | ▼ Sell | Open Market | 163 | $7K | 11/19/2024 | View on chart |
| AZTA | ▲ Buy | Grant | 6,921 | $287K | 11/15/2024 | View on chart |
| AZTA | ▼ Sell | Other | 584 | $30K | 5/20/2024 | View on chart |
| AZTA | ▲ Buy | Grant | 311 | $20K | 1/31/2024 | View on chart |
| AZTA | ▲ Buy | Grant | 1,374 | $75K | 11/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.